Bertrand Charles Devaux

Prof. Bertrand Charles Devaux

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2024 in Neurology
Verified
Journal Article
Open access
MSMaurits W. Sanders
Maurits W. Sanders
IWIskander Van der Wolf
Iskander Van der Wolf
FJFloor E. Jansen
Floor E. Jansen
EAEleonora Aronica
Eleonora Aronica
CHChristoph Helmstaedter
Christoph Helmstaedter
A(as the European Epilepsy Brain Bank Consortium (EEBB)
as the European Epilepsy Brain Bank Consortium (EEBB)
Patients with presumed nonlesional focal epilepsy-based on either MRI or histopathologic findings-have a lower success rate of epilepsy surgery compared with lesional patients. In this study, we aimed to characterize a large group of patients with focal epilepsy who underwent epilepsy surgery despite a normal MRI and had no lesion on histopathology. Determinants of their postoperative seizure outcomes were further studied. We designed an observational multicenter cohort study of MRI-negative and histopathology-negative patients who were derived from the European Epilepsy Brain Bank and underwent epilepsy surgery between 2000 and 2012 in 34 epilepsy surgery centers within Europe. We collected data on clinical characteristics, presurgical assessment, including genetic testing, surgery characteristics, postoperative outcome, and treatment regimen. Of the 217 included patients, 40% were seizure-free (Engel I) 2 years after surgery and one-third of patients remained seizure-free after 5 years. Temporal lobe surgery (adjusted odds ratio [AOR]: 2.62; 95% CI 1.19-5.76), shorter epilepsy duration (AOR for duration: 0.94; 95% CI 0.89-0.99), and completely normal histopathologic findings-versus nonspecific reactive gliosis-(AOR: 4.69; 95% CI 1.79-11.27) were significantly associated with favorable seizure outcome at 2 years after surgery. Of patients who underwent invasive monitoring, only 35% reached seizure freedom at 2 years. Patients with parietal lobe resections had lowest seizure freedom rates (12.5%). Among temporal lobe surgery patients, there was a trend toward favorable outcome if hippocampectomy was part of the resection strategy (OR: 2.94; 95% CI 0.98-8.80). Genetic testing was only sporadically performed. This study shows that seizure freedom can be reached in 40% of nonlesional patients with both normal MRI and histopathology findings. In particular, nonlesional temporal lobe epilepsy should be regarded as a relatively favorable group, with almost half of patients achieving seizure freedom at 2 years after surgery-even more if the hippocampus is resected-compared with only 1 in 5 nonlesional patients who underwent extratemporal surgery. Patients with an electroclinically identified focus, who are nonlesional, will be a promising group for advanced molecular-genetic analysis of brain tissue specimens to identify new brain somatic epilepsy genes or epilepsy-associated molecular pathways.

5 July 2022 in Neurology
Verified
Journal Article
Closed access
PDF file
FCFrancine Chassoux
Francine Chassoux
CMCharles Mellerio
Charles Mellerio
ALAgathe Laurent
Agathe Laurent
ELElisabeth Landre
Elisabeth Landre
BTBaris Turak
Baris Turak
BDBertrand Charles Devaux
Bertrand Charles Devaux
Background: Focal cortical dysplasia type 2 (FCD2) in the central region can cause drug-resistant epilepsy for which surgery remains challenging because of subsequent functional deficits. Advances in imaging and surgical techniques have progressively improved outcome. We aimed to assess the benefits on epilepsy and the functional risks after FCD2 resections in these highly eloquent areas. Methods: We retrospectively studied all consecutive patients with histologically confirmed FCD2 located in the central region operated between 2000 and 2019 at a single center. We analyzed electro-clinical and imaging features (including fMRI), seizure outcome, early and late postoperative neurological status correlating to anatomo-functional areas (primary motor cortex: PMC, paracentral lobule: PCL, supplementary motor area: SMA, precentral gyrus: PrCG, post-central gyrus: PoCG, central operculum: COp). Results: 60 patients (35 females; 7–65 years) were included in the study. Epilepsy was characterized by early onset, high seizure frequency with clusters (30-90/day), drop-attacks and status epilepticus. Ictal semiology included sensory-motor auras, motor and postural manifestations, and post-ictal motor deficits. EEG and stereo-EEG patterns were like those typically recorded in FCD2. MRI was positive in 63% and FDG-PET in 86% of the patients. fMRI demonstrated activations close to the FCD2 (59%) or minor reorganization (41%) but none within the lesion. Seizure-free outcome (2–20-year follow-up) was obtained in 53 patients (88%), including 37 achieving Engel class IA (62%), correlating with complete FCD2 removal. Early transitory post-operative deficits occurred in 52 patients (87%), which were severe in 19, mostly after PMC, PCL and SMA resections, while PrCG, PoCG and COp resections were associated with minor/moderate deficits. Total recovery was observed in 21/52 patients (40%), while a permanent deficit (>2 years) persisted in 31 (minor: 19, moderate; 9, major: 3). The best outcome [seizure-freedom without deficit (48%) or with minor deficit (28%)] was significantly more frequent in children (p=0.025). Antiseizure medications were discontinued in 28 patients (47%). Quality of life correlated with seizure-free outcome and absence of postoperative deficit; 43 patients (72%) reported a schooling or socio-professional improvement. Discussion: Excellent seizure outcome and low rates of major permanent disability can be achieved after central FCD2 resections despite functional risks. Classification of evidence: Due to its retrospective nature, this study provides class IV evidence that good seizure outcomes with minor additional deficits can be achieved after epilepsy surgery in the central region.

7 May 2008 in Neurochirurgie
Verified
Journal Article
Closed access
BDBertrand Charles Devaux
Bertrand Charles Devaux
FCF. Chassoux
F. Chassoux
ELE. Landré
E. Landré
BTB. Turak
B. Turak
ZAZ. Abou-Salma
Z. Abou-Salma
FRF.-X. Roux
F.-X. Roux

1 March 2018 in Neurochirurgie
Verified
Journal Article
Closed access
CCC. Champeaux
C. Champeaux
PRP. Rousseau
P. Rousseau
BDBertrand Charles Devaux
Bertrand Charles Devaux
FNF. Nataf
F. Nataf
ATA. Tauziède-Espariat
A. Tauziède-Espariat

28 April 2022 in Brain and Spine
Verified
Journal Article
Open access
FMFumihiro Matano
Fumihiro Matano
TPThibault Passeri
Thibault Passeri
RARosaria Viola Abbritti
Rosaria Viola Abbritti
BCBreno Camara
Breno Camara
CMCiro Mastantuoni
Ciro Mastantuoni
SFSébastien Froelich
Sébastien Froelich
• The transorbital approach combining eyebrow incision and crescent-shaped craniotomy increases the surgical freedom to access the anterior and middle skull-base. • The technic allows the use of both endoscope and microscope. • The concept is at the crossroad between the supraorbital keyhole and endoscopic trans-orbital approach.

1 September 2012 in Journal of Neurosurgery
Verified
Journal Article
Closed access
PDF file
JPJohan Pallud
Johan Pallud
EDEdouard Dezamis
Edouard Dezamis
EAEtienne Audureau
Etienne Audureau
BDBertrand Charles Devaux
Bertrand Charles Devaux
RSRaphaëlle Souillard-Scemama
Raphaëlle Souillard-Scemama
PVPascale Varlet
Pascale Varlet
In this study, the authors address whether neurofilament protein (NFP) expression can be used as an independent prognostic factor in primary glioblastoma multiformes (GBMs). Three hundred and two consecutive adult patients with newly diagnosed supratentorial primary GBMs were analyzed (January 2000–August 2008). Detailed data regarding clinical, imaging, and pathological findings, oncological treatments, and outcomes were recorded. Neurofilament protein immunoexpression served to identify NFP-positive tumor cells (normal entrapped neurons and mature ganglion-like cells excluded). Neurofilament-positive cells were identified in 177 GBMs (58.6%). Patients with NFP-positive GBMs were younger (p < 0.0001), and their GBMs presented with more temporal lobe tumor localization (p = 0.029) and more cortical involvement (p = 0.0003). Neurofilament-negative GBMs presented with more ventricular contact (p < 0.0001) and more tumor midline crossing (p = 0.03). Median overall survival and progression-free survival (PFS) were 13.0 and 7.6 months, respectively, for NFP-positive GBMs, and 7.0 and 5.1 months, respectively, for NFP-negative GBMs. Multivariate analysis revealed NFP immunoexpression, tumor midline crossing, complete resection, and radiotherapy combined with chemotherapy as independent factors associated with overall survival. Neurofilament protein–positive immunoexpression was associated with longer overall survival (hazard ratio [HR] 0.54, 95% CI 0.40–0.74; p < 0.0001) and longer PFS (HR 0.71, 95% CI 0.53–0.96; p = 0.02). Neurofilament protein–positive immunoexpression represents a strong, therapeutically independent prognostic factor for primary supratentorial GBM clinical outcome among adult patients. Neurofilament protein–GBM's unique pathological features are not only associated with distinct clinical and anatomical behavior, but are also predictive of overall patient survival and PFS. Neurofilament protein immunoexpression may help identify a distinct subgroup of primary GBMs with a favorable prognosis, which should be considered in the design of future targeted therapies.